Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Belapectin |
Synonyms | |
Therapy Description |
Belapectin (GR-MD-02) is a galectin inhibitor, which leads to apoptosis in galectin over expressing cells (PMID: 24130706, PMID: 31812510). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Belapectin | GR-MD-02 | Belapectin (GR-MD-02) is a galectin inhibitor, which leads to apoptosis in galectin over expressing cells (PMID: 24130706, PMID: 31812510). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02575404 | Phase I | Belapectin Pembrolizumab | GR-MD-02 Plus Pembrolizumab in Melanoma Patients | Completed | USA | 0 |
NCT02117362 | Phase I | Ipilimumab Belapectin | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | Completed | USA | 0 |